HRP20140327T1 - Lentiviralni vektori pseudotipizirani sa glikoproteinom ovojnice virusa sindbis - Google Patents

Lentiviralni vektori pseudotipizirani sa glikoproteinom ovojnice virusa sindbis Download PDF

Info

Publication number
HRP20140327T1
HRP20140327T1 HRP20140327AT HRP20140327T HRP20140327T1 HR P20140327 T1 HRP20140327 T1 HR P20140327T1 HR P20140327A T HRP20140327A T HR P20140327AT HR P20140327 T HRP20140327 T HR P20140327T HR P20140327 T1 HRP20140327 T1 HR P20140327T1
Authority
HR
Croatia
Prior art keywords
polypeptide
virus
lentiviral vector
antigen
seq
Prior art date
Application number
HRP20140327AT
Other languages
English (en)
Inventor
James M. Allen
Neal S. Van Hoeven
Jin Zhong Li
Derek D. Sloan
Thomas W. Dubensky
Original Assignee
Immune Design Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42727669&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20140327(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Immune Design Corp filed Critical Immune Design Corp
Publication of HRP20140327T1 publication Critical patent/HRP20140327T1/hr
Publication of HRP20140327T4 publication Critical patent/HRP20140327T4/hr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/50Colon
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • A61K39/001154Enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • A61K39/001154Enzymes
    • A61K39/001156Tyrosinase and tyrosinase related proteinases [TRP-1 or TRP-2]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • A61K39/001184Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • A61K39/001184Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001186MAGE
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • A61K39/001184Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001188NY-ESO
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • A61K39/00119Melanoma antigens
    • A61K39/001191Melan-A/MART
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • A61K39/00119Melanoma antigens
    • A61K39/001192Glycoprotein 100 [Gp100]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • A61K39/001193Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
    • A61K39/001194Prostate specific antigen [PSA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • A61K39/001193Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
    • A61K39/001195Prostate specific membrane antigen [PSMA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/46Cellular immunotherapy
    • A61K39/461Cellular immunotherapy characterised by the cell type used
    • A61K39/4615Dendritic cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/46Cellular immunotherapy
    • A61K39/462Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622Antigen presenting cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/46Cellular immunotherapy
    • A61K39/464Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643Vertebrate antigens
    • A61K39/4644Cancer antigens
    • A61K39/464499Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5256Virus expressing foreign proteins
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/15011Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15022New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/15011Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/36011Togaviridae
    • C12N2770/36111Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36141Use of virus, viral particle or viral elements as a vector
    • C12N2770/36145Special targeting system for viral vectors
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)

Claims (23)

1. Čestica lentiviralnog vektora naznačena time da sadrži: (a) ovojnicu koja sadrži (i) glikoprotein E2 virusa Sindbis sa sekvencom SEQ ID NO:1 u kojoj je 160X odsutan ili je amino kiselina koja nije glutaminska kiselina, ili varijanta SEQ ID NO:1 koja ima barem 80% identičnosti sa SEQ ID NO:1, te pri čemu je 160X odsutan ili je amino kiselina koja nije glutaminska kiselina, koja može inficirati dendritske stanice; pri čemu E2 nije dio kondenziranog proteina sa Sindbis virusom E3; te (b) genom lentiviralnog vektora koji sadrži jednu ili više sekvenci od interesa.
2. Čestica lentiviralnog vektora prema zahtjevu 1, naznačena time da 160X je odsutan ili glicin, alanin, valin, leucin ili izoleucin, kao što je na primjer izabran od glicina, valina, leucina ili izoleucina.
3. Čestica lentiviralnog vektora prema zahtjevu 1 ili 2, naznačena time da varijanta glikoproteina E2 ima barem jednu izmijenjenu amino kiselinu, da bi se smanjio njegov neto pozitivni naboj.
4. Čestica lentiviralnog vektora prema zahtjevu 3, naznačena time da je barem jedna amino kiselina koja je promijenjena da bi se smanjio njegov neto pozitivni naboj odabrana od lizina 70, lizina 76 ili lizina 159 iz SEQ ID NO:1, te poželjno gdje su supstitucije neovisno odabrane od glutaminske kiseline ili asparaginske kiseline.
5. Čestica lentiviralnog vektora prema zahtjevu 1, naznačena time da varijanta E2 sekvence je ostatak amino kiselina 66 do 488 iz SEQ ID NO:3, ostatci amino kiselina 66 do 488 iz SEQ ID NO: 4, ili ostatci amino kiselina 66 do 486 iz SEQ ID NO:5; (varijante 1, 2, i 3).
6. Čestica lentiviralnog vektora prema bilo kojem zahtjevu od 1-5, naznačena time da je varijanta u kojoj je sekvenca sa ostatcima 71-75 iz SEQ ID NO:1 nepromijenjena ili ima jednu ili dvije supstitucije koje ne utječu na sposobnost varijante da inficira DC-ove, ali ne mijenja broj amino kiselina u toj regiji.
7. Čestica lentiviralnog vektora prema bilo kojem zahtjevu od 1-6, naznačena time da sekvenca od interesa eksprimira produkt koji je antigen agensa koji uzrokuje bolest ili oboljela stanica.
8. Čestica lentiviralnog vektora prema bilo kojem zahtjevu od 1-6 naznačena time da sekvenca od interesa kodira tumor-specifični antigen, proizvoljno NY-ESO-1, MAGE, MART-1/Melan-A, BAGE, RAGE, antigen linije melanocit-melanom, kao gp100, gp75, mda-7, tirozinaza ili sa tirozinazom povezan protein; antigen karcinoma renalne stanice, 5T4, SM22-alfa, karbonska anhidraza I, karbonska anhidraza IX (također poznata kao G250), faktori, koji induciraju hipoksiju (proizvoljno, HIF-1 alfa ili HIF-2alfa), VEGF ili membranski antigen specifičan za prostatu (PSMA), prostata specifični antigen (PSA), prostatičnu kiselu fosfatazu, šest-transmembranski epoitelialni antigen prostate (STEAP), NKX3.1, epitop proteini/peptidi dobiveni iz gena koji su mutirali u stanicama tumora in ili genima transkribiranim na različitim razinama u tumoru u usporedbi sa normalnim stanicama, kao što su enzim telomeraze, survivin, mezotelin, mutirani ras, preuređeni bcr/abl, Her2/neu, mutiran ili divljeg soja p53, citokrom P450 1B1, abnormalno eksprimirane intronske sekvence kao što su N-acetilglukozaminiltransferaza-V; klonalno preuređene imunoglobulinske gene koji generiraju jedinstvene idiotipove u mijelomu ili u limfomima B-stanica; epitop proteini/peptidi dobiveni iz onkoviralnih procesa, kao što su proteini E6 ili E7humanog papiloma virusa; ili ne-mutirani onkofetalni proteini sa tumorskom-selektivnom ekspresijom, kao što su karcinoembrionski antigen ili alfa-fetoprotein.
9. Čestica lentiviralnog vektora prema bilo kojem zahtjevu od 1-7, naznačena time da sekvenca od interesa kodira antigen dobiven iz virusa, kao HIV ili SIV antigen, polipeptid adenovirusa, polipeptid alfavirusa, polipeptid kalicivirusa, npr., antigen kalicivirus kapsida, polipeptid koronavirusa, polipeptid distemper virusa, polipeptid Ebola virusa, polipeptid enterovirusa, polipeptid flavivirusa, polipeptid virusa hepatitisa (AE), npr., jezgru ili površinski antigen hepatitisa B, ili glikoproteine E1 ili E2virusa hepatitisa C, jezgru, ili ne-strukturne proteine, polipeptid virusa herpesa, npr., virus herpes simplex ili glikoprotein virusa varicela zoster, polipeptid virusa imunodeficijencije, npr., ovojnicu ili proteazu humanog virusa imunodeficijencije, polipeptid virusa infekcijskog peritonitisa, polipeptid virusa influence, npr., hemaglutinin influence A, neuraminidaza; ili nukleoprotein, polipeptid virusa leukemije, polipeptid virusa Marburg, polipeptid ortomikso virusa, polipeptid papiloma virusa, polipeptide parainfluenca virusa, npr., hemaglutinin/neuraminidaza, polipeptid paramiksovirusa, polipeptid parvovirusa, polipeptid pestivirusa, polipeptid picorna virusa, npr., polipeptid poliovirusa kapsid, polipeptid virus boginja, npr., polipeptid vaccinia virusa, polipeptid virusa bjesnoće, npr., glikoprotein G virusa bjesnoće, polipeptid reovirusa, polipeptid retrovirusa, ili polipeptid rotavirusa.
10. Pripravak koji sadrži česticu lentiviralnog vektora prema bilo kojem zahtjevu od 1-9, naznačen time da pripravak ima IU od barem 105/mL.
11. Sustav pakiranja lentiviralnog vektora za proizvodnju pseudotipizirane čestice lentiviralnog vektora prema bilo kojem zahtjevu od 1-9, ili pripravak prema zahtjevu 10, naznačen time da sadrži: (i) prvu molekulu nukleinske kiseline koja kodira glikoprotein E2 virusa Sindbis prema zahtjevu 1 (a)(i), te; (ii) drugu molekulu nukleinske kiseline koja kodira gag i pol proteine, (iii) treću molekulu nukleinske kiseline koja kodira rev; (iv) genom lentiviralnog vektora koji sadrži sekvencu od interesa; te (v) pakirajuću stanicu.
12. Sustav pakiranja lentiviralnog vektora prema zahtjevu 11, naznačen time da: (a) pol protein ima ne-funkcionalnu integrazu; i/ili (b) pol protein ima ne-funkcionalnu integrazu sa D64V mutacijom; i/ili (c) genom lentiviralnog vektora je ne-integrirajući lentiviralni genom; i/ili (d) pakirajuća stanica je stabilno pretvorena sa (ii) i (iii); i/ili (e) pakirajuća stanica je transfektirana sa (i) i (iv).
13. Izolirana molekula nukleinske kiseline naznačena time da sadrži nukleotidnu sekvencu koja kodira glikoprotein E2 ili varijantu prema zahtjevu 1 (a)(i), ili prema bilo kojem od zahtjeva 2-9.
14. Molekula nukleinske kiseline prema zahtjevu 13 naznačena time da protein je poliprotein Sindbis E3/E2/6K/E1 koji je obrađen tako da protein E2 nije dio spojenog proteina sa E3 kada je ugrađen u ovojnicu virusa.
15. Molekula nukleinske kiseline prema zahtjevu 14, naznačena time da E3 sekvenca odgovara (a) ostatcima 1-65 iz SEQ ID NO:20, ili (b) njihovoj varijanti koja ima barem 80% identičnosti sekvence sa ostatcima 1-65 iz SEQ ID NO:20, pri čemu ostatci 62-65 su RSKR (SEQ ID NO: 27), a varijanta se može ugraditi u pseudotipiziranu ovojnicu virusa.
16. Postupak dobivanja čestica lentiviralnog vektora prema bilo kojem zahtjevu od 1-9, ili pripravak prema zahtjevu 10, naznačen time da sadrži kultiviranje stanica za pakiranje prema zahtjevu 11.
17. Lentiviralna čestica prema bilo kojem zahtjevu od 1-9, ili pripravak prema zahtjevu 10, naznačena time da genom lentiviralnog vektora (a) ima deaktivirano ili samostalno-deaktivirano 3' dugo terminalno ponavljanje (LTR); i/ili (b) sadrži U3 element kojem nedostaju barem jedan od: (i) sekvenca pojačivača; (ii) TATA box (iii) mjesto Sp1 (iv) mjesto NK-kapa B i (v) polipurinski trakt (PPT); i/ili (c) sadrži nukleotidnu sekvencu iz SEQ ID NO: 21, 22 ili 23; i/ili, (d) sadrži nukleotidnu sekvencu koja kodira faktor starenja/stimulacije dendritske stanice.
18. Čestica lentiviralnog vektora prema bilo kojem zahtjevu od 1-9, ili pripravak prema zahtjevu 10, naznačeni time da su za uporabu u postupku liječenja subjekta koji je čovjek ili životinja,te proizvoljno sadrži dostavu ex vivo čestica lentiviralnog vektora u dendritske stanice.
19. Čestica lentiviralnog vektora prema bilo kojem zahtjevu od 1-9, ili pripravak prema zahtjevu 10, naznačeni time da su za uporabu kod induciranja antigen-specifičnog imunološkog odgovora, proizvoljno humoralnog imunološkog odgovora i/ili celularnog imunološkog odgovora.
20. Cjepivo za terapiju ili profilaksu naznačeno time da sadrži čestice lentiviralnih vektora prema bilo kojem zahtjevu od 1-9, ili pripravak prema zahtjevu 10, te farmaceutski prihvatljivu pomoćnu tvar.
21. Cjepivo za terapiju ili profilaksu prema zahtjevu 20 naznačeno time da dodatno sadrži adjuvant.
22. Cjepivo za terapiju ili profilaksu prema zahtjevu 21, naznačeno time da adjuvant je adjuvant sa formulom (I): [image] pri čemu A1 i A2 su neovisno odabrani iz skupine koja sadrži vodik, fosfat, te soli fosfata, a dijelovi R1, R2, R3, R4, R5 i R6 su neovisno odabrani iz skupine koja sadrži hidrokarbil koji ima 3 do 23 atoma ugljika, koji predstavlja C3-C23.
23. Cjepivo za terapiju ili profilaksu prema zahtjevu 22, naznačeno time da (a) A1 je fosfat ili fosfatna sol i A2 je vodik, te (b) (i) R1, R3, R5 i R6 su C11-C20 alkil, i R2 i R4 su C12-C20 hidrokarbil; ili (ii) R1, R3, R5 i R6 su C11 alkil, i R2 i R4 su C13 hidrokarbil; ili (iii) R1, R3, R5 i R6 su undecil, i R2 i R4 su tridecil.
HRP20140327TT 2009-07-24 2014-04-04 Lentiviralni vektori pseudotipizirani sa glikoproteinom ovojnice virusa sindbis HRP20140327T4 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22849109P 2009-07-24 2009-07-24
PCT/US2010/042870 WO2011011584A1 (en) 2009-07-24 2010-07-22 Lentiviral vectors pseudotyped with a sindbis virus envelope glycoprotein
EP10737715.2A EP2456786B2 (en) 2009-07-24 2010-07-22 Lentiviral vectors pseudotyped with a sindbis virus envelope glycoprotein

Publications (2)

Publication Number Publication Date
HRP20140327T1 true HRP20140327T1 (hr) 2014-05-09
HRP20140327T4 HRP20140327T4 (hr) 2017-11-03

Family

ID=42727669

Family Applications (2)

Application Number Title Priority Date Filing Date
HRP20140327TT HRP20140327T4 (hr) 2009-07-24 2014-04-04 Lentiviralni vektori pseudotipizirani sa glikoproteinom ovojnice virusa sindbis
HRP20181996TT HRP20181996T1 (hr) 2009-07-24 2018-11-27 Ne-integrirajući lentiviralni vektori

Family Applications After (1)

Application Number Title Priority Date Filing Date
HRP20181996TT HRP20181996T1 (hr) 2009-07-24 2018-11-27 Ne-integrirajući lentiviralni vektori

Country Status (28)

Country Link
US (3) US20110064763A1 (hr)
EP (2) EP2770061B1 (hr)
JP (4) JP2013500015A (hr)
KR (1) KR101790187B1 (hr)
CN (1) CN102482329B (hr)
AU (1) AU2010276194B2 (hr)
BR (1) BR112012001653A2 (hr)
CA (1) CA2768938C (hr)
CY (1) CY1121159T1 (hr)
DK (2) DK2770061T3 (hr)
EA (1) EA032403B1 (hr)
ES (2) ES2455544T5 (hr)
HK (1) HK1201557A1 (hr)
HR (2) HRP20140327T4 (hr)
HU (1) HUE043032T2 (hr)
IL (1) IL217679A (hr)
LT (1) LT2770061T (hr)
ME (1) ME01720B (hr)
MX (1) MX2012001075A (hr)
NZ (1) NZ597804A (hr)
PL (2) PL2456786T5 (hr)
PT (2) PT2770061T (hr)
RS (2) RS58042B1 (hr)
SG (1) SG177744A1 (hr)
SI (2) SI2770061T1 (hr)
SM (1) SMT201400041B (hr)
TR (1) TR201819229T4 (hr)
WO (1) WO2011011584A1 (hr)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2657737T3 (es) * 2009-07-15 2018-03-06 Calimmune Inc. Vector dual para la inhibición del virus de la inmunodeficiencia humana
BR112013020875A2 (pt) * 2011-02-15 2019-09-24 Immune Design Corp método para indução de uma resposta imune específica para um imunógeno em um indivíduo.
JP6054942B2 (ja) * 2011-04-08 2016-12-27 イミューン デザイン コーポレイション 免疫原性組成物、ならびに体液性および細胞性免疫応答を誘発するための該組成物の使用方法
WO2013116656A1 (en) * 2012-02-03 2013-08-08 Emory University Immunostimulatory compositions, particles, and uses related thereto
US9486539B2 (en) 2012-03-26 2016-11-08 The Regents Of The University Of California Nipah virus envelope pseudotyped lentiviruses and methods of their use
US8323662B1 (en) * 2012-03-30 2012-12-04 Immune Design Corp. Methods useful for generating highly mannosylated pseudotyped lentiviral vector particles comprising a Vpx protein
US9713635B2 (en) 2012-03-30 2017-07-25 Immune Design Corp. Materials and methods for producing improved lentiviral vector particles
AU2013237900B2 (en) * 2012-03-30 2017-07-27 Immune Design Corp. Lentiviral vector particles having improved transduction efficiency for cells expressing DC- SIGN
CN107540730B (zh) 2012-05-16 2021-07-16 免疫设计公司 用于hsv-2的疫苗
EP2943203A4 (en) * 2013-01-11 2016-08-24 Scripps Research Inst METHOD AND COMPOSITIONS FOR INCREASING THE TRANSDUCTION EFFICIENCY OF RETROVIRAL VECTORS
GB201308772D0 (en) * 2013-05-15 2013-06-26 Imp Innovations Ltd Vectors
PL3116900T3 (pl) 2014-03-09 2021-03-08 The Trustees Of The University Of Pennsylvania Kompozycje użyteczne w leczeniu niedoboru transkarbamylazy ornitynowej (otc)
JP2017522312A (ja) 2014-07-15 2017-08-10 イミューン デザイン コーポレイション Tlr4アゴニストアジュバント及びレンチウイルスベクターを用いたプライム・ブーストレジメン
EP3838296A1 (en) * 2015-01-21 2021-06-23 Cornell University Viral vectors for prophylaxis and therapy of hemoglobinopathies
CN112481211B (zh) * 2015-01-26 2024-07-05 儿童医院公司 免疫调节性提高的细胞及其使用和生产方法
BR112017019776B1 (pt) * 2015-03-18 2020-07-28 Omnicyte proteínas de fusão que compreendem glicoproteínas de superfície de alfavírus modificadas e antígeno associado a tumor e métodos dos mesmos
DK3283658T3 (da) 2015-05-18 2020-05-18 Calimmune Inc Fremgangsmåder til at diskriminere mellem HIV-1 og lentivirus-vektorer
EP3347374A1 (en) 2015-09-09 2018-07-18 Immune Design Corp. Ny-eso-1 specific tcrs and methods of use thereof
BR112018008911A2 (pt) * 2015-11-09 2018-11-27 Immune Design Corp composições compreendendo vetores lentivirais que expressam il-12 e métodos de uso das mesmas
WO2017083356A1 (en) 2015-11-09 2017-05-18 Immune Design Corp. A retroviral vector for the administration and expression of replicon rna expressing heterologous nucleic acids
WO2017147119A1 (en) * 2016-02-23 2017-08-31 Immune Design Corp. Multigenome retroviral vector preparations and methods and systems for producing and using same
BR112018067565A2 (pt) * 2016-03-04 2019-02-05 Univ New York vetores de vírus que expressam múltiplos epítopos de antígenos associados a tumor para induzir imunidade antitumor
US11078282B2 (en) 2016-04-15 2021-08-03 Alpine Immune Sciences, Inc. CD80 variant immunomodulatory proteins and uses thereof
AU2017250358B2 (en) 2016-04-15 2023-06-01 Alpine Immune Sciences, Inc. ICOS ligand variant immunomodulatory proteins and uses thereof
EP3235828A1 (en) * 2016-04-21 2017-10-25 Genethon Stable pseudotyped lentiviral particles and uses thereof
EP3235908A1 (en) 2016-04-21 2017-10-25 Ecole Normale Superieure De Lyon Methods for selectively modulating the activity of distinct subtypes of cells
US11471488B2 (en) 2016-07-28 2022-10-18 Alpine Immune Sciences, Inc. CD155 variant immunomodulatory proteins and uses thereof
CA3032120A1 (en) 2016-07-28 2018-02-01 Alpine Immune Sciences, Inc. Cd155 variant immunomodulatory proteins and uses thereof
US11834490B2 (en) 2016-07-28 2023-12-05 Alpine Immune Sciences, Inc. CD112 variant immunomodulatory proteins and uses thereof
EP3872180A1 (en) 2016-10-20 2021-09-01 Alpine Immune Sciences, Inc. Secretable variant immunomodulatory proteins and engineered cell therapy
WO2018148180A2 (en) 2017-02-07 2018-08-16 Immune Design Corp. Materials and methods for identifying and treating cancer patients
EP3596116B1 (en) 2017-03-16 2023-09-06 Alpine Immune Sciences, Inc. Pd-l1 variant immunomodulatory proteins and uses thereof
CA3054068A1 (en) 2017-03-16 2018-09-20 Alpine Immune Sciences, Inc. Cd80 variant immunomodulatory proteins and uses thereof
JP2020511144A (ja) 2017-03-16 2020-04-16 アルパイン イミューン サイエンシズ インコーポレイテッド Pd−l2バリアント免疫調節タンパク質及びその使用
CN110869507A (zh) 2017-05-08 2020-03-06 旗舰先锋创新V股份有限公司 促进膜融合的组合物和其用途
TW201925223A (zh) 2017-10-18 2019-07-01 美商艾爾潘免疫科學有限公司 變異型icos 配位體免疫調節蛋白及相關組合物及方法
US11116833B2 (en) * 2018-02-08 2021-09-14 George Mason University Method and system for inactivating virus infectivity for producing live-attenuated vaccines
WO2019241758A1 (en) 2018-06-15 2019-12-19 Alpine Immune Sciences, Inc. Pd-1 variant immunomodulatory proteins and uses thereof
CN113348244A (zh) * 2018-11-23 2021-09-03 维拉治疗有限公司 Vsv嵌合载体
CA3120868A1 (en) 2018-11-30 2020-06-04 Alpine Immune Sciences, Inc. Cd86 variant immunomodulatory proteins and uses thereof
JP7495435B2 (ja) 2019-06-14 2024-06-04 ザ ジェイ. デビッド グラッドストーン インスティテューツ、 ア テスタメンタリー トラスト エスタブリッシュド アンダー ザ ウィル オブ ジェイ. デビッド グラッドストーン 治療用干渉粒子による免疫不全ウイルス感染を処置するための組成物及び方法
US20220307050A1 (en) * 2019-08-01 2022-09-29 The Regents Of The University Of California Non-viral transgenesis
CN110982842B (zh) * 2019-12-31 2023-04-18 山西大学 一种慢病毒表达载体的设计及应用
KR20240028975A (ko) 2021-04-08 2024-03-05 사나 바이오테크놀로지, 인크. Cd8-특이적 항체 구조체들 및 이의 조성물
US20230340627A1 (en) * 2022-04-05 2023-10-26 Bio-Rad Laboratories, Inc. Analysis of viral particles by digital assay
WO2023220603A1 (en) 2022-05-09 2023-11-16 Regeneron Pharmaceuticals, Inc. Vectors and methods for in vivo antibody production
WO2023240124A1 (en) 2022-06-07 2023-12-14 Regeneron Pharmaceuticals, Inc. Pseudotyped viral particles for targeting tcr-expressing cells

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4703004A (en) 1984-01-24 1987-10-27 Immunex Corporation Synthesis of protein with an identification peptide
US4569794A (en) 1984-12-05 1986-02-11 Eli Lilly And Company Process for purifying proteins and compounds useful in such process
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
CA1283827C (en) 1986-12-18 1991-05-07 Giorgio Cirelli Appliance for injection of liquid formulations
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4937190A (en) 1987-10-15 1990-06-26 Wisconsin Alumni Research Foundation Translation enhancer
CA1339684C (en) 1988-05-17 1998-02-24 Peter H. Quail Plant ubquitin promoter system
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
US5298420A (en) 1990-08-03 1994-03-29 Tanox Biosystems, Inc. Antibodies specific for isotype specific domains of human IgM and human IgG expressed or the B cell surface
TW279133B (hr) 1990-12-13 1996-06-21 Elan Med Tech
US5328483A (en) 1992-02-27 1994-07-12 Jacoby Richard M Intradermal injection device with medication and needle guard
JPH08504091A (ja) 1992-09-22 1996-05-07 メディカル・リサーチ・カウンシル 外部表面に非ウィルス性ポリペプチドを提示する組換えウィルス
US6534051B1 (en) 1992-11-20 2003-03-18 University Of Medicine And Dentistry Of New Jersey Cell type specific gene transfer using retroviral vectors containing antibody-envelope fusion proteins and wild-type envelope fusion proteins
US5279552A (en) 1993-01-11 1994-01-18 Anton Magnet Intradermal injection device
US5997501A (en) 1993-11-18 1999-12-07 Elan Corporation, Plc Intradermal drug delivery device
WO1996017072A2 (en) 1994-11-30 1996-06-06 Chiron Viagene, Inc. Recombinant alphavirus vectors
US5660835A (en) 1995-02-24 1997-08-26 East Carolina University Method of treating adenosine depletion
WO1997005266A1 (en) 1995-07-25 1997-02-13 Introgene B.V. Methods and means for targeted gene delivery
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
US5910434A (en) 1995-12-15 1999-06-08 Systemix, Inc. Method for obtaining retroviral packaging cell lines producing high transducing efficiency retroviral supernatant
FR2747046B1 (fr) 1996-04-05 1998-06-19 Univ Paris Curie Nouveaux vaccins issus de plasmovirus
EP0961830A1 (en) 1997-01-29 1999-12-08 Neurosearch A/S EXPRESSION VECTORS AND METHODS FOR $i(IN VIVO) EXPRESSION OF THERAPEUTIC POLYPEPTIDES
US6432699B1 (en) * 1997-03-28 2002-08-13 New York University Viral vectors having chimeric envelope proteins containing the IgG-binding domain of protein A
US6531123B1 (en) 1997-05-01 2003-03-11 Lung-Ji Chang Lentiviral vectors
ZA988446B (en) 1997-09-18 2000-03-22 Res Dev Foundation Production of vaccines using arthropod vectored viruses.
WO1999013905A1 (en) 1997-09-18 1999-03-25 The Trustees Of The University Of Pennsylvania Receptor-binding pocket mutants of influenza a virus hemagglutinin for use in targeted gene delivery
US6218181B1 (en) 1998-03-18 2001-04-17 The Salk Institute For Biological Studies Retroviral packaging cell line
US7078483B2 (en) 1998-04-29 2006-07-18 University Of Southern California Retroviral vectors including modified envelope escort proteins
AU763007B2 (en) * 1998-05-22 2003-07-10 Oxford Biomedica (Uk) Limited Retroviral delivery system
EP1165842A4 (en) * 1999-03-16 2004-07-07 Dana Farber Cancer Inst Inc LENTIVIRAL VECTOR SYSTEMS FOR SCREENING LARGE QUANTITIES
DK1175497T3 (da) 1999-04-14 2010-05-31 Novartis Vaccines & Diagnostic Præparater og fremgangsmåder til generering af et immunrespons ved udnyttelse af alfavirusbaserede vektorsystemer
EP1046651A1 (en) 1999-04-19 2000-10-25 Koninklijke Universiteit Nijmegen Composition and method for modulating dendritic cell-T interaction
CA2392010A1 (en) 1999-08-27 2001-03-08 Regents Of The University Of California Use of lentiviral vectors for antigen presentation in dendritic cells
CA2388676A1 (en) 1999-10-13 2001-04-19 Chiron Corporation Method of obtaining cellular immune responses from proteins
US7241275B2 (en) 1999-10-14 2007-07-10 Becton, Dickinson And Company Intradermal needle
US6776776B2 (en) 1999-10-14 2004-08-17 Becton, Dickinson And Company Prefillable intradermal delivery device
US6494865B1 (en) 1999-10-14 2002-12-17 Becton Dickinson And Company Intradermal delivery device including a needle assembly
US20020193740A1 (en) 1999-10-14 2002-12-19 Alchas Paul G. Method of intradermally injecting substances
US6569143B2 (en) 1999-10-14 2003-05-27 Becton, Dickinson And Company Method of intradermally injecting substances
US6627442B1 (en) * 2000-08-31 2003-09-30 Virxsys Corporation Methods for stable transduction of cells with hiv-derived viral vectors
US20040091853A1 (en) * 2001-03-02 2004-05-13 Hazuda Daria J. Viral reporter particles
WO2002101057A1 (fr) * 2001-06-08 2002-12-19 Dnavec Research Inc. Transfert genique dans des cellules souches embryonnaires de primate a l'aide d'un virus de l'immunodeficience simienne de pseudo type vsv-g utilise comme vecteur
US7737124B2 (en) 2001-09-13 2010-06-15 California Institute Of Technology Method for expression of small antiviral RNA molecules with reduced cytotoxicity within a cell
AU2002336517B2 (en) 2001-09-13 2008-09-11 California Institute Of Technology Method for producing transgenic animals
US7195916B2 (en) 2001-09-13 2007-03-27 California Institute Of Technology Method for expression of small antiviral RNA molecules within a cell
ATE439041T1 (de) 2001-09-13 2009-08-15 California Inst Of Techn Verfahren zur expression von kleinen antiviralen rna-molekülen innerhalb einer zelle
US6971999B2 (en) 2001-11-14 2005-12-06 Medical Instill Technologies, Inc. Intradermal delivery device and method
ES2374042T3 (es) 2002-02-04 2012-02-13 Becton, Dickinson And Company Dispositivo y método para suministrar o extraer una sustancia a través de la piel.
US7115108B2 (en) 2002-04-02 2006-10-03 Becton, Dickinson And Company Method and device for intradermally delivering a substance
US7047070B2 (en) 2002-04-02 2006-05-16 Becton, Dickinson And Company Valved intradermal delivery device and method of intradermally delivering a substance to a patient
US6780171B2 (en) 2002-04-02 2004-08-24 Becton, Dickinson And Company Intradermal delivery device
KR101002955B1 (ko) * 2002-04-26 2010-12-21 인스티튜트 클레이톤 드 라 리쎄르셰 개선된 키메라 당단백질 및 슈도타입 렌티바이러스 벡터
US7455833B2 (en) 2002-07-15 2008-11-25 Board Of Regents, The University Of Texas System Methods and compositions for treating viral infections using antibodies and immunoconjugates to aminophospholipids
JP5145492B2 (ja) 2002-08-16 2013-02-20 独立行政法人科学技術振興機構 組換えbcgワクチン
AU2003297474A1 (en) 2002-12-18 2004-07-14 Salk Institute For Biological Studies Methods of inhibiting gene expression by rna interference
US7090837B2 (en) 2003-01-21 2006-08-15 The Salk Institute For Biological Studies Compositions and methods for tissue specific targeting of lentivirus vectors
US7556814B2 (en) 2003-10-23 2009-07-07 Karp Nelson M Immunogenic compositions comprising UV-irradiated, psoralen-inactivated, desialated human immunodeficiency virus (HIV) devoid of CD55 and CD59 in the viral membrane
US7108679B2 (en) 2004-03-11 2006-09-19 Becton, Dickinson And Company Intradermal syringe and needle assembly
US20070275873A1 (en) * 2004-04-29 2007-11-29 Heidner Hans W Methods and Compositions Comprising Protein L Immunoglobulin Binding Domains for Cell-Specific Targeting
US20080227736A1 (en) * 2004-06-03 2008-09-18 Regents Of The University Of California, Targeting Pseudotyped Retroviral Vectors
GB0417494D0 (en) 2004-08-05 2004-09-08 Glaxosmithkline Biolog Sa Vaccine
WO2006031996A2 (en) * 2004-09-14 2006-03-23 University Of Pittsburgh Of The Commonwealth System Of Higher Education Targeting viruses using a modified sindbis glycoprotein
RU2007134371A (ru) * 2005-02-16 2009-03-27 Лентиджен Корпорейшн (Us) Лентивирусные векторы и их применение
US20070020238A1 (en) 2005-06-01 2007-01-25 David Baltimore Method of targeted gene delivery using viral vectors
EP2520168B1 (en) * 2006-07-21 2014-03-19 California Institute of Technology Targeted gene delivery for dendritic cell vaccination
DK2068918T4 (da) 2006-09-26 2024-09-02 Access To Advanced Health Inst Vaccinesammensætning omfattende syntetisk adjuvant
CA2698668A1 (en) 2007-09-07 2009-03-19 University Of Georgia Research Foundation, Inc. Synthetic lipid a derivative
EP2222861B1 (en) 2007-12-11 2017-12-06 The University of North Carolina At Chapel Hill Polypurine tract modified retroviral vectors

Also Published As

Publication number Publication date
JP6170952B2 (ja) 2017-07-26
CN102482329B (zh) 2017-11-14
DK2770061T3 (en) 2019-01-07
KR101790187B1 (ko) 2017-10-25
ES2455544T3 (es) 2014-04-16
US20110064763A1 (en) 2011-03-17
ES2702274T3 (es) 2019-02-28
PT2456786E (pt) 2014-03-25
CA2768938A1 (en) 2011-01-27
ME01720B (me) 2014-09-20
HRP20181996T1 (hr) 2019-03-22
HUE043032T2 (hu) 2019-07-29
CY1121159T1 (el) 2020-05-29
EP2456786A1 (en) 2012-05-30
MX2012001075A (es) 2012-05-22
ES2455544T5 (es) 2017-08-16
EP2456786B2 (en) 2017-04-19
DK2456786T4 (en) 2017-08-07
US20160076055A1 (en) 2016-03-17
EP2770061A1 (en) 2014-08-27
SG177744A1 (en) 2012-02-28
PL2456786T3 (pl) 2014-06-30
RS53257B2 (sr) 2018-06-29
PT2770061T (pt) 2018-12-24
US20120039932A1 (en) 2012-02-16
EP2770061B1 (en) 2018-10-24
PL2770061T3 (pl) 2019-02-28
US8187872B2 (en) 2012-05-29
DK2456786T3 (en) 2014-03-24
PL2456786T5 (pl) 2017-10-31
SI2456786T2 (sl) 2017-08-31
RS58042B1 (sr) 2019-02-28
EA032403B1 (ru) 2019-05-31
WO2011011584A1 (en) 2011-01-27
HK1201557A1 (en) 2015-09-04
AU2010276194A1 (en) 2011-11-24
JP2017060535A (ja) 2017-03-30
HRP20140327T4 (hr) 2017-11-03
LT2770061T (lt) 2018-12-27
SMT201400041B (it) 2014-05-07
TR201819229T4 (tr) 2019-01-21
EP2456786B1 (en) 2014-01-08
JP6701280B2 (ja) 2020-05-27
RS53257B (en) 2014-08-29
IL217679A (en) 2016-09-29
BR112012001653A2 (pt) 2016-11-08
JP2015109853A (ja) 2015-06-18
JP2013500015A (ja) 2013-01-07
NZ597804A (en) 2013-10-25
EA201270191A1 (ru) 2012-12-28
KR20120068838A (ko) 2012-06-27
SI2456786T1 (sl) 2014-05-30
JP2018198616A (ja) 2018-12-20
AU2010276194B2 (en) 2012-02-02
SI2770061T1 (sl) 2019-02-28
CA2768938C (en) 2019-05-14
CN102482329A (zh) 2012-05-30

Similar Documents

Publication Publication Date Title
HRP20140327T1 (hr) Lentiviralni vektori pseudotipizirani sa glikoproteinom ovojnice virusa sindbis
ES2898271T3 (es) Antígenos del virus de la inmunodeficiencia humana, vectores, composiciones y métodos de uso de los mismos
CA2967720C (en) Tri-segmented arenaviruses as vaccine vectors
JP6324725B2 (ja) 発現系
ES2707288T3 (es) Partículas de vectores lentivíricos que tienen eficiencia de transducción mejorada para células que expresan DC-SIGN
JP2015512263A5 (hr)
ES2337429T3 (es) Vectores lentivirales para la preparacion de composiciones inmunoterapeuticas.
JP2020039347A (ja) 新規多価ナノ粒子に基づくワクチン
JP2013500015A5 (hr)
ES2632723T3 (es) Virus recombinantes del sarampión que expresan epítopes de antígenos de virus ARN y uso de los virus recombinantes para la preparación de composiciones de vacuna
Bellier et al. DNA vaccines encoding retrovirus-based virus-like particles induce efficient immune responses without adjuvant
Ku et al. Use of lentiviral vectors in vaccination
Lu Combination DNA plus protein HIV vaccines
WO2019123250A1 (en) Methods and compositions for inducing an immune response against hepatitis b virus (hbv)
KR20210114379A (ko) 융합 단백질
US20120164155A1 (en) Chimeric molecules
Von Messling et al. Toward novel vaccines and therapies based on negative-strand RNA viruses
CN112584870A (zh) 用于体内翻译后修饰的组合物和方法
Lundstrom Viral Vectors for COVID-19 Vaccine Development. Viruses 2021, 13, 317
WO2024091962A1 (en) Compositions comprising engineered envelopes to engage cd4 binding site broadly neutralizing antibody precursors
JP2017512499A (ja) モザイクhiv−1配列およびその使用
WO2024003239A1 (en) RECOMBINANT MODIFIED saRNA (VRP) AND VACCINIA VIRUS ANKARA (MVA) PRIME-BOOST REGIMEN
WO2023164457A2 (en) Versatile virus-like-vesicles (vlv) platform for infectious diseases and cancer immunotherapy applications
WO2023235823A1 (en) Ch505 envelopes to engage and mature cd4 binding site neutralizing antibodies
Wiegand et al. Genome Replication-Incompetent Sendai Virus Vaccine Vector Against Respiratory Viral Infections That Is Capable of Eliciting a Broad Spectrum of Specific Immune Response